LA JOLLA, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Fate Therapeutics, Inc. announced today that Dr. Rudolf Jaenisch, M.D., founding member of the Whitehead Institute for Biomedical Research and professor in the Department of Biology, Massachusetts Institute of Technology, has joined the Company’s internationally recognized team of scientific founders dedicated to understanding stem cell biology in human physiology and disease. Dr. Jaenisch is credited with being one of the first to discover the revolutionary mechanisms for “reprogramming” fully-mature adult cells to a stem-like state. The creation of these “reprogrammed” cells, known as induced pluripotent stem (iPS) cells, provides numerous advantages over stem cells sourced from human embryos and has ushered in a new paradigm in stem cell research for modeling human diseases, discovering and testing conventional pharmaceuticals and developing personalized cell replacement therapies.
